Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Vizcaíno, Carolina ^a   Núñez, Luz Elena ^b   Morís, Francisco ^b   Portugal, José ^a  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^b Entrechem   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEMYCAROSIL 3DEXTRO BETA DEXTRO DIGITOXOSYL MITHRAMYCIN SK; EARLY GROWTH RESPONSE FACTOR 1; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; DEMYCAROSYL-3D-DIGITOXOSYLMITHRAMYCIN SK; MITHRAMYCIN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROMOTER REGION; TRANSCRIPTION REGULATION; ANALOGS AND DERIVATIVES; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENETICS; GENOMICS; HUMAN GENOME; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE ONTOLOGY; GENE REGULATORY NETWORKS; GENOME, HUMAN; GENOMICS; HUMANS; OVARIAN NEOPLASMS; PLICAMYCIN; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84905864162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104687     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374: 1371-1382.
3. Kigawa J (2013) New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med 56: 43-50.
4. Hall M, Gourley C, McNeish I, Ledermann J, Gore M, et al. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 108: 250-258.
5. Grivas PD, Kiaris H, Papavassiliou AG (2011) Tackling transcription factors: challenges in antitumor therapy. Trends Mol Med 17: 537-538.
6. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: e1000024.
8. Solár P, Sytkowski AJ (2011) Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett 309: 11-18.
9. Yan C, Higgins PJ (2013) Drugging the undruggable: Transcription therapy for cancer. Biochim Biophys Acta 1835: 76-85.
10. Portugal J, Mansilla S, Vizcaíno C, Barceló F (2011) Promoter-specific transcriptional interference by DNA-binding drugs. Recent Research Development in Biochemistry Vol 8. Kerala: Research Signpost. pp. 45-63.
11. Skubitz AP, Pambuccian SE, Argenta PA, Skubitz KM (2006) Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 148: 223-248. (Pubitemid 44634295)
12. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC (2008) Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 122: 1430-1034.
13. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, et al. (2008) Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14: 3030-3035.
14. Rice GE, Edgell TA, Autelitano DJ (2010) Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer. J Exp Clin Cancer Res 29: 62.
15. Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG (2011) HOX genes in ovarian cancer. J Ovarian Res 4: 16.
16. Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ (2006) Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281: 21433-21444. (Pubitemid 44115482)
17. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, et al. (2006) Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res 34: 1721-1734.
18. Previdi S, Malek A, Albertini V, Riva C, Capella C, et al. (2010) Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 118: 182-188.
19. Lombó F, Menéndez N, Salas JA, Méndez C (2006) The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 73: 1-14.
20. King PD, Perry MC (2001) Hepatotoxicity of chemotherapy. Oncologist 6: 162-176. (Pubitemid 32323455)
21. Remsing LL, González AM, Nur-e-Alam M, Fernández-Lozano MJ, Braña AF, et al. (2003) Mithramycin SK, A novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: Three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc 125: 5745-5753. (Pubitemid 36592899)
22. Barceló F, Scotta C, Ortiz-Lombardía M, Méndez C, Salas JA, et al. (2007) Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences. Nucleic Acids Res 35: 2215-2226. (Pubitemid 47073709)
23. Barceló F, Ortiz-Lombardía M, Martorell M, Oliver M, Méndez C, et al. (2010) DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49: 10543-10552.
24. Pérez M, Baig I, Braña AF, Salas JA, Rohr J, et al. (2008) Generation of new derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosynthesis. Chembiochem 29: 2295-2304.
25. Núñez LE, Nybo SE, González-Sabín J, Pérez M, Menéndez N, et al. (2012) A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. J Med Chem 55: 5813-5825.
26. Zabala D, Braña AF, Florez AB, Salas JA, Méndez C (2013) Engineering precursor metabolite pools for increasing production of antitumor mithramycins in Streptomyces argillaceus. Metab Eng 20: 187-197.
27. Jones DE, Jr., Cui DM, Miller DM (1995) Expression of β-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. Oncogene 10: 2323-2330.
28. Jia Z, Zhang J, Wei D, Wang L, Yuan P, et al. (2007) Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 67: 4878-4885. (Pubitemid 46910196)
29. Vizcaíno C, Mansilla S, Núñez LE, Méndez C, Salas JA, et al. (2012) Novel mithramycins abrogate the involvement of protein factors in the transcription of cell cycle control genes. Biochem Pharmacol 84: 1133-1142.
30. Villamarín S, Mansilla S, Ferrer-Miralles N, Priebe W, Portugal J (2003) A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem 270: 764-770. (Pubitemid 36286589)
31. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
32. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, et al. (2010) PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 38: D204-D210.
33. Cole SW, Yan W, Galic Z, Arevalo J, Zack JA (2005) Expression-based monitoring of transcription factor activity: the TELiS database. Bioinformatics 21: 803-810. (Pubitemid 40439417)
34. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, et al. (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14: 128.
35. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
36. Saeed AI, Sharov V, White J, Li J, Liang W, et al. (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378. (Pubitemid 36184095)
37. Barakat BM, Wang QE, Han C, Milum K, Yin DT, et al. (2010) Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. Int J Cancer 127: 977-988.
38. Davidson B, Alejandro E, Florenes VA, Goderstad JM, Risberg B, et al. (2004) Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 100: 2139-2147. (Pubitemid 38580332)
39. Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, et al. (2010) E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Cancer Res 70: 4613-4623.
40. Oeggerli M, Tian Y, Ruiz C, Wijker B, Sauter G, et al. (2012) Role of KCNMA1 in breast cancer. PLoS One 7: e41664.
41. Minuzzo M, Ceribelli M, Pitarque-Marti M, Borrelli S, Erba E, et al. (2005) Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol 68: 1496-1503. (Pubitemid 41540005)
42. Malek A, Nuñez LE, Magistri M, Brambilla L, Jovic S, et al. (2012) Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7: e35130.
43. Fernández-Guizán A, Mansilla S, Barceló F, Vizcaíno C, Nuñez LE, et al. (2014) The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem Biol Interact 219: 123-132.
44. Kaur M, MacPherson CR, Schmeier S, Narasimhan K, Choolani M, et al. (2011) In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer. BMC Syst Biol 5: 144.
45. Albihn A, Johnsen JI, Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107: 163-224.
46. Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448. (Pubitemid 41540621)
47. Bataller M, Méndez C, Salas JA, Portugal J (2008) Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells. Mol Cancer Ther 7: 2988-2997.
48. Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, et al. (2011) Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst 103: 962-978.